Imugene Ltd · ASX:IMU

Imugene — Investor Presentation (October 2017)

36 slides from Imugene's investor presentation, October 2017

  1. Slide 1: Mimotope Induced B-Cell Antibodies for Immuno-Oncology

    ASX:IMU v MIMOTOPE INDUCED B-CELL ANTIBODIES FOR IMMUNO-ONCOLOGY Leslie Chong | Chief Executive Officer 2H/2017 1

  2. Slide 2: Notice: Forward Looking Statements

    NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other fa

  3. Slide 3: Executive Summary

    EXECUTIVE SUMMARY • Experienced management & board • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her2+ gastric cancer (large unmet medical need by current existing therapies) • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity established • Discovery Pipeline:

  4. Slide 4: What Does Imugene Do?

    WHAT DOES IMUGENE DO? Imugene’s technology can induce a patient’s body v to make its own specific antibodies that target cancer. 4

  5. Slide 5: A Team with Track Record in Drug Development

    A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT Leslie Chong (Sydney, Australia) Prof Ursula Wiedermann (Vienna, Austria) Chief Executive Officer Chief Scientific Officer • Over 19 years of oncology experience in Phase I - III of • Co-inventor of Her-Vaxx; clinical program development • Professor of Va

  6. Slide 6: A Better Way to Make Antibodies to Treat Cancer?

    A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? IN A FACILITY USING B CELLS IN YOUR OWN BODY B Cells are cells in the human VSv body that naturally produce millions of antibodies Teaching B cells to make antibodies For example, Roche’s Herceptin using peptide mimotopes 6

  7. Slide 7: Mimotope: Platform Technology

    MIMOTOPE: PLATFORM TECHNOLOGY A mimotope is a small molecule, often a peptide, which mirrors the structure of an epitope, the specific target an antibody binds to. Because of this property, the mimotope induces an antibody response similar to the one elicited by the epitope. A mimotope causes your B

  8. Slide 8: The Monoclonal Antibody (mAb) Market

    THE MONOCLONAL ANTIBODY (mAb) MARKET • Multiple antibody therapies are approved to treat cancer, for example: Sales in 2016 - Herceptin: >US$6.7 billion - Perjeta: >US$1.8 billion - Rituxan: >US$7.3 billion - YERVOY®: >US$1.0 billion - OPDIVO®: >US$3.7 billion - KEYTRUDA: >US$1.4 billion v Total mon

  9. Slide 9: HER-Vaxx Mimotope: Mechanism of Action

    HER-Vaxx MIMOTOPE: MECHANISM OF ACTION Peptides “mimic” the HER-Vaxx epitope Antibody Secretion Tumor Cell 3 B-cell HER-2/neu EPITOPE = Peptides v Activation Antibody Via helper T- Binding Site cells B-Cell HER-Vaxx attacks the same target as the HER-Vaxx the world’s largest Immunotherapy selling br

  10. Slide 10: HER-Vaxx Is a Phase 1b/2 Stage Mimotope Peptide Therapy for HER2+ Gastric Cancer

    ASX:IMU v HER-Vaxx IS A PHASE 1B/2 STAGE MIMOTOPE PEPTIDE THERAPY BEING DEVELOPED FOR HER2+ GASTRIC CANCER 10

  11. Slide 11: Phase 1 in Breast Cancer, Completed at Medical University of Vienna

    PHASE 1 IN BREAST CANCER, COMPLETED AT MEDICAL UNIVERSITY OF VIENNA- SINGLE AGENT, NO CHEMO DESIGN *RESULTS CLINICAL ENDPOINTS • 10 patients • Patients developed anti-HER-2 antibodies 1 Safety and Tolerability • All late stage breast cancer • Induction of cytokines (Th1 biased; IFNγ) patients • Indu

  12. Slide 12: HER-Vaxx Inhibits HER-2 Expressing Cells

    HER-VAXX INHIBITS HER-2 EXPRESSING CELLS HER-Vaxx antibodies demonstrate anti-tumour effect Combination with Herceptin shows significantly by inhibiting validated HER-2+ gastric cell line higher inhibition than Herceptin alone. Effect of Trastuzumab and IMU-131 sera on Percentage of Inhibition NCI-N

  13. Slide 13: Phase 1b/2 in Gastric Cancer

    PHASE 1B/2, IN GASTRIC CANCER Phase 1b lead-in Phase 2 • Open label • Open label • ~70 patients from sites in Asia • ~Up to 18 patients in 3 cohorts of up to 6 pts per cohort • Combination with chemo • Combination with chemo/cisplatin • Randomized • Primary Endpoints: • Endpoints: - TBD PFS and/or O

  14. Slide 14: Our Investigators and Study Centers

    OUR INVESTIGATORS AND STUDY CENTERS CHINA THOMAS YAU YEE CHAO Taipei Veterans Queen Mary Hospital General Hospital The University of Hong Kong) MYANMAR TAIWAN CHAIYUT CHIA-JUI YEN National Cheng CHAROENTUM LAOS Kung University Maharaj Nakorn Hospital Chiang Mai Hospital JEDZADA MANEECHAVAKAJORNv SUE

  15. Slide 15: Gastric Market Opportunity

    GASTRIC MARKET OPPORTUNITY • Asia is the largest market for gastric cancer globally • Gastric cancer is the second leading cause of cancer mortality in the world & its management, especially in advanced stages, has evolved Chemotherapy relatively little • ~1 million gastric cancer cases per year; ~1

  16. Slide 16: Market Opportunity

    MARKET OPPORTUNITY Indications Gastric Cancer Breast Cancer 1 million cases of newly diagnosed cases, 1.67m cases of newly diagnosed cases; Incidence ~190k are HER2+* ~418k are HER2+* Varies in breast cancer type. 0.5m Prognosis Poor. Median survival is 7-10 months deaths per year % of Patients HER2

  17. Slide 17: Imugene Pipeline

    IMUGENE PIPELINE HER-Vaxx (IMU-131) Discovery Pre-Clinical Phase IB Phase 2 Open Label Randomized, Chemotherapy Controlled Study in Gastric Cancer + or - HER-Vaxx *Combination Study in breast HER-Vaxx + cancer Herceptin *Herceptin Resistant/Failed Study HER-Vaxx + Chemotherapy v *HER2+ in bladder an

  18. Slide 18: Mimotope B-Cell Peptide Therapy

    ASX:IMU v MIMOTOPE B-CELL PEPTIDE THERAPY 18

  19. Slide 19: Mimotope Proposed Development Path 2017-2018

    MIMOTOPE PROPOSED DEVELOPMENT PATH 2017-2018 2H, 2018:Toxicology, 2H, 2018: GMP 2H, 2017 : 1H, 18:Formal pre- immunotox, safety Mimotope Candidate manufacturing clinical pharmacology (cont. dev of 2-3 1H, 2018: CMC additional candidate) manufacturing v Proposed Phase l Cohort 5 Expansions Assumption

  20. Slide 20: Imugene Discovery Pipeline

    IMUGENE DISCOVERY PIPELINE MIMOTOPE IMMUNE ID OF PROGRAM PRE-IND WORK CLINICAL DEVELOPMENT IDENTIFICATION CHARACTERIZATION CANDIDATE HER-Vaxx /Her2 Combo *Mimotope #2 *Mimotope #3 Her2 / *Mimotope Combo v Combo #3? TBD DISCOVERY ID OF CANDIDATE PRE-IND WORK Arginine Modulator 20

  21. Slide 21: Milestones and Deliverables

    MILESTONES AND DELIVERABLES PROGRAM 2H2017 1H2018 2H2018 1H2019 2H2019 On-going data Initiate IST around ISTs Interim studies Early Early Early Ph1b Ph1b RP2D and Patients Data Interim Data Ongoing efficacy Patients Patient Patient Data Safety Data Start Enrolled On On Ph2 data data enrolled Data Da

  22. Slide 22: Financial Summary

    FINANCIAL SUMMARY ASX:IMU Top 5 shareholders (as at Sept. 2017) Market Cap No. of Shares % Capital $33.1M AUD, $25.7M USD (14/Jul/17) Platinum Asset Ordinary Shares 2.365 billion 240,227,753 10.14% Management 12 month price National Nominees 0.7 cents – 2.1 cents AUD 95,548,708 4.03% range Limited A

  23. Slide 23: Executive Summary

    EXECUTIVE SUMMARY • Experienced management & board • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her2+ gastric cancer (large unmet medical need by current existing therapies) • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity established • Discovery Pipeline:

  24. Slide 24: Appendix

    ASX:IMU APPENDIX v SR. TEAM MEMBER ON MARKETED ONCOLOGY DRUGS 24

  25. Slide 25: Herceptin (Trastuzumab) Mild Treatment Related Side Effects

    HERCEPTIN ® (TRASTUZUMAB) MILD TREATMENT RELATED SIDE EFFECTS • Diarrhea • Redness or irritation at injection (IV) site • Muscle/joint/back pain • Stomach or abdominal pain v • Headache • Sleep problems (insomnia) • Nausea and vomiting (may be severe) • Weight loss 25

  26. Slide 26: Herceptin (Trastuzumab) Serious Treatment Related Side Effects

    HERCEPTIN ® (TRASTUZUMAB) SERIOUS TREATMENT RELATED SIDE EFFECTS – BLACK BOX WARNING1 • CARDIOMYOPATHY: Herceptin can result in sub-clinical and clinical cardiac failure manifesting as CHF (congestive heart failure), and decreased LVEF ( left ventricular ejection fraction). • INFUSION REACTIONS: PUL

  27. Slide 27: Phase 1a Study Design

    PHASE IA STUDY DESIGN* ADMINISTRATION & READOUT SCHEDULE Patient inclusion criteria • Metastatic breast cancer • HER2 +, ++ • ER/PR pos. • Life expectance > 4 mo v Primary endpoint D0 D28 D56 D84 • Safety & Tolerability Secondary endpoint Vaccination with 10µg • Immunogenicity of each peptide antige

  28. Slide 28: Patient Characteristics – Ages 55-84

    PATIENT CHARACTERISTICS – AGES 55-84 * Patient ID Age Metastatic disease since Prior chemotherapy Current antihormonal therapy 1 55 Oct. 2006 no Anastrozol 2 66 May 2004 yes (1 adj) Fulvestrant 3 84 Mar. 1999 no Anastrozol 4 79 Sept. 2003 no Anastrozol 5 67 Apr. 2004 no Fulvestrant v 6 69 Sept. 2004

  29. Slide 29: Safety and Tolerability – Few Grade 1 Local Reactions, None Systemic

    SAFETY AND TOLERABILITY – FEW GRADE 1 LOCAL REACTIONS, NONE SYSTEMIC* Patient ID Local vaccination reaction grade Systemic grade 3/4 toxicity 1 1 no 2 0 no 3 0 no 4 1 no 5 1 v no 6 0 no 7 0 no 8 0 no 9 1 no 10 0 no * Breast Cancer Res Treat. 2010 Feb;119(3):673-83. 29

  30. Slide 30: Phase 1 Secondary Endpoint – Immunologic Responses

    PHASE 1 SECONDARY ENDPOINT – IMMUNOLOGIC RESPONSES Western blot analysis demonstrating increase of Her-2/neu-specific IgG post- vaccination in patient: ANTIBODY (lane 1) Polyclonal rabbit anti Her-2/neu antibody was used as positive control RESPONSES (lane 2) serum of a healthy volunteer as negative

  31. Slide 31: Phase 1 – Reduction in Regulatory T Cells

    Cancer PatientsPhase vs. Healthy Controls I - Regulatory T cells: Cancer Patients vs. Healthy Controls REDUCTION IN REGULATORY T CELLS* p=0.033 pre-vaccination post-vaccination p=0.033 pre-vaccination post-vaccination CD4+Foxp3+ Data.026 CD4+Foxp3+ Data.026 10.0 p=0.007 p=0.007 10.0 1.06 8.32 1.06 8

  32. Slide 32: Encouraging Immunogenicity, Even at Low Dose, with No Cardiotoxicity

    ENCOURAGING IMMUNOGENICITY, EVEN AT LOW DOSE, AND IN PATIENTS AGES UP TO 84 YEARS, WITH NO CARDIOTOXICITY Antibody and cellular responses in human Pat. # Peptide-specific ab P4, P6, P7 HER2- specific ab Infl. HIT IL-2, IFNγ, TNF T reg • Immunogenicity in 8/10 patients in Phase 1 study with 10 µg of

  33. Slide 33: Tumor Growth Inhibition In Vivo

    TUMOR GROWTH INHIBITION IN VIVO* Time to disease progression • Prolonged time to Cumulative proportion tumor-free Untreated Tentanus toxoid disease progression Peptide Peptide + IL12 • Immunization of c-neu transgenic mice IL12 (recognized HER2 cancer model) with tetanus toxoid-conjugated peptides P

  34. Slide 34: Mimotope

    MIMOTOPE Peptides “mimic” the epitope EPITOPE = Antibody Binding Site HER2+ Cancer v Cell Mimotope Anti HER-2 Peptides Patient’s B Cells Antibody make antibodies B-Cell against HER-2 HER-2 Receptor 34

  35. Slide 35: Phase 1b/2 Enhanced Gastric Formulation

    PHASE 1B/2 ENHANCED GASTRIC FORMULATION Her-2/neu specific IgG kinetic, after last immunization 1.60 3 w. after 3 doses vacc. 1.40 1.20 8 w. after 3 doses vacc. 1.00 16 w. after 3 doses vacc. 0.80 6 mo. after 3 doses vacc. OD 0.60 v Pre-immunization 0.40 0.20 0.00 P467-CRM-Montanide (µg) In the mous

  36. Slide 36: Leslie Chong

    Leslie Chong Chief Executive Officer leslie.chong@imugene.com v +61 458 040 433 36

Imugene — Investor Presentation (October 2017) on 6ix